argenx SE (NASDAQ:ARGX) Stock Position Decreased by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 69.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 610 shares of the company's stock after selling 1,390 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in argenx were worth $375,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Morse Asset Management Inc purchased a new stake in shares of argenx during the fourth quarter worth about $154,000. Moore Capital Management LP increased its position in shares of argenx by 54.5% during the fourth quarter. Moore Capital Management LP now owns 34,000 shares of the company's stock valued at $20,910,000 after acquiring an additional 12,000 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in argenx by 1,086.6% in the fourth quarter. Lazard Asset Management LLC now owns 70,637 shares of the company's stock worth $43,440,000 after purchasing an additional 64,684 shares during the last quarter. Iron Triangle Partners LP purchased a new stake in argenx during the fourth quarter valued at approximately $21,525,000. Finally, Focus Partners Wealth purchased a new position in shares of argenx during the 4th quarter worth $201,000. Institutional investors own 60.32% of the company's stock.

Wall Street Analyst Weigh In

ARGX has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. Baird R W raised shares of argenx from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 13th. HC Wainwright restated a "buy" rating and issued a $720.00 target price on shares of argenx in a research note on Tuesday, April 8th. Wedbush reiterated an "outperform" rating and set a $715.00 price objective on shares of argenx in a research note on Friday, April 11th. Finally, Oppenheimer raised their target price on shares of argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. One equities research analyst has rated the stock with a hold rating, twenty have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $698.11.

argenx Stock Performance

NASDAQ:ARGX traded up $4.09 during trading hours on Monday, hitting $569.72. The company's stock had a trading volume of 105,912 shares, compared to its average volume of 324,083. The business's 50-day moving average is $591.63 and its two-hundred day moving average is $613.54. The company has a market capitalization of $34.79 billion, a PE ratio of -647.43 and a beta of 0.57. argenx SE has a 52-week low of $356.38 and a 52-week high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. As a group, analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.